11919237

Source:http://linkedlifedata.com/resource/pubmed/id/11919237

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0030705, umls-concept:C0246415, umls-concept:C0278488, umls-concept:C0282460, umls-concept:C0332174, umls-concept:C0728747
pubmed:issue	7
pubmed:dateCreated	2002-3-28
pubmed:abstractText	To evaluate the safety and efficacy of weekly docetaxel plus trastuzumab in women with HER-2-overexpressing metastatic breast cancer. Efficacy was correlated with serum HER-2 extracellular domain (ECD) levels.
pubmed:grant	http://linkedlifedata.com/resource/pubmed/grant/K23 CA82119
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8309333
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized, http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Phytogenic, http://linkedlifedata.com/resource/pubmed/chemical/Paclitaxel, http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2, http://linkedlifedata.com/resource/pubmed/chemical/Taxoids, http://linkedlifedata.com/resource/pubmed/chemical/docetaxel, http://linkedlifedata.com/resource/pubmed/chemical/trastuzumab
pubmed:status	MEDLINE
pubmed:month	Apr
pubmed:issn	0732-183X
pubmed:author	pubmed-author:ArunBanuB, pubmed-author:BooserDanielD, pubmed-author:CristofanilliMassimoM, pubmed-author:EsmaeliBitaB, pubmed-author:EstevaFrancisco JFJ, pubmed-author:FritscheHerbert AHA, pubmed-author:GuerraLaura TLT, pubmed-author:HortobagyiGabriel NGN, pubmed-author:MurrayJames LJL, pubmed-author:PusztaiLajosL, pubmed-author:SmithTerry LTL, pubmed-author:SneigeNourN, pubmed-author:ValeroVicenteV
pubmed:issnType	Print
pubmed:day	1
pubmed:volume	20
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1800-8
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:11919237-Adult, pubmed-meshheading:11919237-Aged, pubmed-meshheading:11919237-Antibodies, Monoclonal, pubmed-meshheading:11919237-Antibodies, Monoclonal, Humanized, pubmed-meshheading:11919237-Antineoplastic Agents, Phytogenic, pubmed-meshheading:11919237-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:11919237-Breast Neoplasms, pubmed-meshheading:11919237-Disease Progression, pubmed-meshheading:11919237-Drug Administration Schedule, pubmed-meshheading:11919237-Female, pubmed-meshheading:11919237-Gene Expression Regulation, Neoplastic, pubmed-meshheading:11919237-Humans, pubmed-meshheading:11919237-In Situ Hybridization, Fluorescence, pubmed-meshheading:11919237-Middle Aged, pubmed-meshheading:11919237-Paclitaxel, pubmed-meshheading:11919237-Receptor, erbB-2, pubmed-meshheading:11919237-Taxoids, pubmed-meshheading:11919237-Time Factors, pubmed-meshheading:11919237-Treatment Outcome, pubmed-meshheading:11919237-Up-Regulation
pubmed:year	2002
pubmed:articleTitle	Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.
pubmed:affiliation	Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. festeva@mdanderson.org
pubmed:publicationType	Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't, Clinical Trial, Phase II